Incyte (INCY) Long-Term Deferred Tax (2017 - 2026)
Incyte (INCY) reported Long-Term Deferred Tax of $452.5 million for Q1 2026, down 41.15% on a YoY basis from $768.9 million in Q1 2025, and down 12.18% quarter-over-quarter from $515.3 million in Q4 2025.
Incyte (INCY) Long-Term Deferred Tax (2017 - 2026) Analysis & Trends
Incyte has reported Long-Term Deferred Tax for 10 years, with the latest figure at $452.5 million in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Deferred Tax fell 41.15% year-over-year to $452.5 million; the trailing twelve-month figure through Mar 2026 stood at $452.5 million (down 41.15% YoY), and the FY2025 full-year result was $515.3 million, down 32.38% from the prior year.
- Long-Term Deferred Tax for Q1 2026 stood at $452.5 million, down from $515.3 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $768.9 million in Q1 2025, with the low at $426.8 million in Q3 2022.
- Historically, Long-Term Deferred Tax has averaged $579.2 million across 5 years, with a median of $532.5 million in 2023.
- Annual changes were most pronounced in 2023 — Long-Term Deferred Tax soared 37.98% — and 2026, when it sank 41.15%.
- Incyte's Long-Term Deferred Tax stood at $457.9 million in 2022, then soared by 37.98% to $631.9 million in 2023, then advanced by 20.6% to $762.1 million in 2024, then tumbled by 32.38% to $515.3 million in 2025, then slipped by 12.18% to $452.5 million in 2026.
- The last three Long-Term Deferred Tax figures came in at $452.5 million (Q1 2026), $515.3 million (Q4 2025), and $528.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 452.52 Mn |
| Dec 31, 2025 | 515.29 Mn |
| Sep 30, 2025 | 528.14 Mn |
| Jun 30, 2025 | 652.28 Mn |
| Mar 31, 2025 | 768.90 Mn |
| Dec 31, 2024 | 762.07 Mn |
| Sep 30, 2024 | 762.31 Mn |
| Jun 30, 2024 | 729.56 Mn |
| Mar 31, 2024 | 666.57 Mn |
| Dec 31, 2023 | 631.89 Mn |
| Sep 30, 2023 | 564.39 Mn |
| Jun 30, 2023 | 532.51 Mn |
| Mar 31, 2023 | 494.75 Mn |
| Dec 31, 2022 | 457.94 Mn |
| Sep 30, 2022 | 426.84 Mn |
| Jun 30, 2022 | 434.87 Mn |
| Mar 31, 2022 | 465.37 Mn |
| Dec 31, 2021 | 467.54 Mn |
| Dec 31, 2020 | 2.05 Mn |
| Dec 31, 2019 | 1.65 Mn |